Trading Update – 6 July 2016
(“Craneware”, “the Group” or the “Company”)
Trading Update, Significant Contract win and Notice of Results
6 July 2016 – Craneware (AIM: CRW.L), the market leader in Value Cycle solutions for the US healthcare market, provides an update on trading for the year ended 30 June 2016.
The Board is pleased to confirm the Group’s third consecutive year of record sales performance and a return to double digit growth at the revenue and adjusted EBITDA level.
The Group has seen greater than 60% growth in the value of ‘New Sales’ contracts signed of c$58m (2015 $35.9m) with the average new contract length being maintained at 5 years.
Included in the year’s sales success are two significant contracts. The first announced on 2 February 2016 was for a 50 hospital group in excess of $7.5m revenue over its five year life. In addition to this the Company is pleased to announce that it finished the year with a further multi-hospital group contract win. Starting in FY17, the contract is expected to deliver revenue greater than $8m during the next five years, as the hospital network rolls out multiple Craneware core value cycle solutions.
In accordance with the Company’s revenue recognition policy, the majority of the revenue resulting from all sales will be recognised over future periods, adding to the Group’s long term visibility of revenue under contract. Accordingly the Group expects to report an increase of 11% in revenues and 10% in adjusted EBITDA for the year ended 30 June 2016.
Other key performance indicators continue to be positive. The Group continued to renew hospitals that were due for renewal in the year at an average of above 100% (by $ value) and customer retention continues to be significantly higher than the industry norm.
Strong cash generation resulted in cash reserves in excess of $47m at 30 June 2016 (2015 $41.8m).
Keith Neilson, CEO of Craneware plc commented, “US Healthcare providers continue to address the challenges the new value based re-imbursement environment brings. We believe our continued sales growth demonstrates the strategic importance of Craneware and its Value Cycle solutions to them as they meet these challenges. The ongoing investment we are making to develop solutions that discover, convert and optimise value for healthcare providers, combined with our own historical sales successes, double digit revenue and adjusted EBITDA growth, give management confidence in its ability to deliver continued future growth as well as increasing stakeholder value.” The Company will announce its Full Year Results on 6 September 2016.
The Company will announce its Full Year Results on 6 September 2016.
For further information, please contact:
- +44 (0)131 550 3100
- Keith Neilson, CEO
- Craig Preston, CFO
- +44 (0)20 7418 8900
- Dan Webster
- Adrian Trimmings
- +44 (0)208 004 4218
- Caroline Forde
- Hilary Buchanan
Craneware is the leader in automated value cycle solutions that help US provider organisations discover, convert and optimise assets to achieve best clinical outcomes and financial performance. Founded in 1999, Craneware has headquarters in Edinburgh, Scotland with offices in Atlanta, Boston and Phoenix employing over 200 staff. Craneware’s market-driven, SaaS solutions normalise disparate data sets, bringing in up to-date regulatory and financial compliance data to deliver value at the points where clinical and operational data transform into financial transactions, creating actionable insights that enable informed tactical and strategic decisions. To learn more, visit craneware.com and thevaluecycle.com.
You might also like...
Aug 1, 2018 | Announcements
1 August 2018 - Craneware (AIM: CRW.L), the market leader in Value Cycle solutions for the US healthcare market, is pleased to announce the appointment of Investec Bank plc as the Company's Joint Broker with immediate effect. Peel Hunt...read more
Jul 10, 2018 | Announcements
10 July 2018 - Craneware (AIM: CRW.L), the market leader in Value Cycle solutions for the US healthcare market, provides an update on trading for the year ended 30 June 2018. The Group is pleased to announce continued outstanding...read more
Apr 17, 2018 | Announcements
Schedule 6, Block Admission Period to 15 April 2018 This block admission announcement, as required by the AIM Rules, is made every six months and relates to the number of shares that have been issued and allotted during this six month...read more